In 2023, we continued to reimagine medicine to improve and extend people’s lives. Our performance shows the progress we are we are making in delivering on our purpose and creating sustainable value for society.

Achieving major innovation milestones

In a world where many diseases don’t have a treatment option, how can we bring possibility to people living with serious illnesses every day? It starts with our research and development teams, who push the boundaries of scientific discovery and turn breakthroughs into medicines that change lives. Read more about innovation.

Broadening access to medicines

The best medicines are those that reach the people who need them. We work together with partners to find new ways to bring our medicines to more people and places faster. Read more about access to medicines.

Advancing our commitment to our people, to environmental sustainability and to acting with integrity

Helping people living with disease takes more than innovative science. It takes a community of people who challenge and inspire each other to push the limits of what’s possible, while acting with integrity in all circumstances. It also takes a commitment to the health of the planet, which is inextricably linked to human health. Read more about how we unleash the power of our people, about environmental sustainability, and about how we maintain high ethical standards.

Delivering sustainable financial performance

Novartis delivered a very strong performance in 2023, supported by sales of key products across our core therapeutic areas and growth in core operating income, underscoring the progress we are making in advancing our strategy. Read more about our business performance.

Joerg Reinhardt, Chair of the Board of Directors

Chair's letter

The shift from taking a broad market approach to going deep into select medical areas to achieve category leadership is set to guide our strategy in future.

Joerg Reinhardt, Chair of the Board of Directors

Vas Narasimhan, Chief Executive Officer

CEO's letter

Our very strong financial and R&D performance underscores the benefits of our focused strategy and the progress we are making in creating value for shareholders and society.

Vas Narasimhan, Chief Executive Officer

* The Novartis in Society Integrated Report 2023 includes non-IFRS financial measures such as core R&D spend from continuing operations. A definition of non-IFRS measures used by Novartis, and further details, including reconciliation tables, can be found in “Item 5. Operating and Financial Review and Prospects” of the Novartis Annual Report 2023.